CD274 and colorectal carcinoma: The incidence of intrinsic resistance to anti-PD-1 and anti-PD-L1 in patients with MSI-H CRC was 31% (95% CI 0.20–0.43) and 27% (95% CI 0.12–0.42), respectively (Figure 4B).